William D. Waddill - Mar 1, 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill
Stock symbol
PTGX
Transactions as of
Mar 1, 2024
Transactions value $
-$327,619
Form type
4
Date filed
3/1/2024, 08:45 PM
Previous filing
Jan 16, 2024
Next filing
Apr 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $79K +13K +108.13% $6.09 25K Mar 1, 2024 Direct
transaction PTGX Common Stock Sale -$407K -13K -51.95% $31.34 12K Mar 1, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -13K -100% $0.00* 0 Mar 1, 2024 Common Stock 13K $6.09 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 These stock options are fully vested.